UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~May 2311, 2022

PARALLAX HEALTH SCIENCES, INC.

(Exact name of Company as specified in its charter)

Nevada	000-52534	46-4733512
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
3415 S. Sepulveda Blvd, Suite 1100-6592 Los Angeles, CA 90034 (Address of principal executive offices) (888) 263-9799 (Registrant’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company		þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.		¨

As used in this current report and unless otherwise indicated, the terms "we", "us", "our", “Company”, and “Parallax” mean Parallax Health Sciences, Inc., a Nevada corporation, and its subsidiaries, unless otherwise indicated.

ITEM 51.0201 ~~DEPARTURE~~ENTRY OFINTO ~~DIRECTORS~~A ORMATERIAL ~~PRINCIPAL~~DEFINITIVE ~~OFFICERS, ELECTION OF DIRECTORS; APPOINTMENT OF OFFICERS~~AGREEMENT

~~Election~~On May 11, 2022, pursuant to a unanimous resolution of the Company’s Board of Directors, the Company and its wholly owned subsidiary, Parallax Behavioral Health, Inc. (“PBH” or “Seller”), executed an Intellectual Property Purchase Agreement (the “Purchase Agreement”) for the sale of certain intellectual property (the “Intellectual Property”), as defined within the Purchase Agreement, to Data Health Partners, Inc., a privately held Delaware corporation (“DHPI” or “Buyer”). The Purchase Agreement is effective April 13, 2022, and includes the following consideration to Seller for the transfer of all rights, title and interest in and to the Intellectual Property to Buyer:

~~Effective March 23, 2022, at~~ 1~~:15~~.An amaggregate ~~PST, pursuant to an Action by Written Consent~~ of ~~Shareholders Holding a Majority in Interest in the Company dated March 23~~3, ~~2022~~960,344 ~~the~~shares ~~following~~of ~~individuals~~Buyer’s ~~were~~common ~~elected~~stock to ~~serve~~be asissued to the Company'’s ~~Board~~shareholders of ~~Directors,~~record toon ~~serve until~~ the ~~election~~Record Date of ~~new~~April ~~directors~~13, by2022 (the ~~shareholders~~“Parallax ofShareholders”); ~~the Company or resignation or removal:~~and

~~·Dr~~2.An ~~David~~Anti-Dilution L.Agreement ~~Stark~~providing for certain protections for the Parallax Shareholders; and

~~·Mr~~3.A ~~John~~corporate LPromissory Note in the principal sum of twenty million dollars ($20,0000,000), bearing interest at a rate of three percent (3%) per annum, and maturing in ten (10) years (the “Note”). ~~Ogden~~ The Note is secured by the Intellectual Property, as defined within the Intellectual Property Pledge and Security Agreement; and

~~·Ms~~4.A ~~Calli~~royalty Rof two and one-half percent (2.5%) ~~Bucci~~of Net Proceeds from the monetization of the Intellectual Property, as defined within the Royalty Agreement.

The ~~following~~foregoing ~~individuals~~disclosure ~~were~~set forth in this Section 1.01 does not ~~re-elected~~purport to be complete, and is qualified in its entirety by reference to the Intellectual Property Purchase Agreement filed herewith as ~~Board~~Exhibit ~~members:~~10.1 of this Current Report and incorporated by reference herein.

~~·Mr.~~Purpose ~~Jorn~~and ~~Gorlach~~ Consideration

~~·Mr.~~Parallax ~~Nathaniel~~has T.entered ~~Bradley~~ into this transaction to help the Company meet its financial obligations and generate value for its shareholders.

~~Appointment~~DHPI ofhas ~~Chairman~~entered ofinto this transaction in an effort to monetize the ~~Board~~Intellectual Property through licensing and ~~Election~~joint ofventures, ~~Officers:~~and to prosecute possible infringement through litigation.

~~Effective~~The ~~March~~consideration ~~25,~~provided ~~2022,~~to ~~Dr.~~Parallax ~~David~~has L.been ~~Stark~~based ~~was~~upon ~~unanimously~~potential ~~appointed~~sources asof ~~Chairman~~revenues offor the ~~Board~~Intellectual ~~and~~Property ~~elected~~from toprospective ~~serve~~licensing asand ~~President~~recovery of ~~the~~financial ~~Company~~damages ~~and~~from ~~its subsidiaries~~infringement. ~~Dr. Stark formerly served as the Company’s President between March 1, 2020, until his resignation for personal reasons on August 16, 2021. The Company is pleased to welcome him back.~~

~~Termination~~About ofData ~~Officer:~~Health Partners

OnThe ~~March~~primary 26focus of the Data Health Partners, ~~2022~~Inc. business is in the commercialization of intellectual property through business development, licensing endeavors, and enforcement of intellectual property services and products. Ms. ~~Sonia~~Calli ~~Choi,~~Bucci ~~the~~serves ~~Company~~as DHPI’s ~~interim~~ Chief ~~Executive~~Financial Officer ~~since~~and ~~September~~is 14a member of its Board of Directors, ~~2021~~and is also Parallax’s Chief Financial Officer and Corporate Secretary, ~~was~~and ~~terminated~~a inmember ~~her~~of ~~role~~Parallax’s asBoard ~~interim~~of ~~CEO~~Directors.

~~Current~~ITEM ~~Directors~~2.01 ~~and~~COMPLETION ~~Officers:~~OF ACQUISITION OR DISPOSITION OF ASSETS

The ~~following~~disclosures ~~represents~~set ~~the~~forth ~~Company’s~~in ~~Directors~~Item ~~and~~1.01 ~~Officers~~are ~~after~~incorporated ~~the~~into ~~effects~~this ofItem ~~the~~2.01 ~~changes~~by ~~referenced above:~~reference.

~~Board~~ITEM ~~of Directors Dr~~9.01FINANCIAL ~~David~~STATEMENTS L.AND ~~Stark Chairman Mr. John L. Ogden Board Member Ms. Calli R. Bucci Board Member Officers Dr. David L. Stark President Ms. Calli R. Bucci Chief Financial Officer Secretary, Treasurer~~EXHIBITS

~~Family~~(b) ~~Relationships~~Pro Forma Financial Information.

~~There~~Pro ~~are~~forma nofinancial ~~family~~information ~~relationships~~relative ~~with~~to ~~any~~the ofdisposition transaction is not included in this Current Report on Form 8-K. Such pro forma financial information will be filed within 71 calendar days after the ~~Company's~~date ~~Directors~~on ~~and~~which ~~Officers~~this Current Report on Form 8-K is required to be filed.

~~SIGNATURE~~(d) Exhibits.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit

Number

Description of Exhibit

Filing Reference

10.1

Intellectual Property Purchase Agreement

Filed herewith.

		PARALLAX HEALTH SCIENCES, INC.
Dated: March 28, 2022		/s/ Calli R. Bucci
		Calli R. Bucci
		Chief Financial Officer

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PARALLAX HEALTH SCIENCES, INC.



Dated: May 11, 2022		/s/ David L. Stark
		David L. Stark
		President

Filing Compare · PARALLAX HEALTH SCIENCES, INC.